Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.060
-0.010 (-0.93%)
Sep 10, 2026, 2:29 PM EDT - Market open
Milestone Pharmaceuticals Employees
Milestone Pharmaceuticals had 38 employees as of December 31, 2025. The number of employees increased by 5 or 15.15% compared to the previous year.
Employees
38
Change (1Y)
5
Growth (1Y)
15.15%
Revenue / Employee
$61,658
Profits / Employee
-$2,210,816
Market Cap
149.37M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 38 | 5 | 15.15% |
| Dec 31, 2024 | 33 | -14 | -29.79% |
| Dec 31, 2023 | 47 | 8 | 20.51% |
| Dec 31, 2022 | 39 | 10 | 34.48% |
| Dec 31, 2021 | 29 | 1 | 3.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| LENZ Therapeutics | 152 |
| Codexis | 146 |
| Molecular Partners AG | 134 |
| Caribou Biosciences | 97 |
| Tenaya Therapeutics | 70 |
| Jyong Biotech | 27 |
| Outlook Therapeutics | 17 |
MIST News
- 2 days ago - Milestone Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 7 days ago - Milestone Pharmaceuticals announces NMPA approval of etripamil for PSVT - TheFly
- 7 days ago - Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - GlobeNewsWire
- 8 days ago - Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes - GlobeNewsWire
- 20 days ago - Milestone Pharmaceuticals enrolls first patient in ReVeRA-301 pivotal trial - TheFly
- 20 days ago - Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) - GlobeNewsWire
- 21 days ago - Cantor starts Milestone Pharmaceuticals at Overweight, sees 200% upside - TheFly